Skip to main content

11.10.2015 | Original Article | Ausgabe 3/2016

Tumor Biology 3/2016

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer

Tumor Biology > Ausgabe 3/2016
Baoying Yuan, Changshun Wu, Xingwen Wang, Dan Wang, Huiling Liu, Ling Guo, Xiang-An Li, Junqing Han, Hong Feng
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4141-4) contains supplementary material, which is available to authorized users.
Baoying Yuan and Changshun Wu contributed equally to this work.
This work was supported by grants from the National Natural Science Foundation of China (No. 81201865 and 81202307), and Shandong Science and Technology Development Planning (No. 2011GSF11843 and 2012G0021822).


Scavenger receptor class B type I (SR-BI) has been linked to the development and progression of breast cancer. However, its clinical significance in breast cancer remains unclear. Here, we evaluated SR-BI expression in a well-characterized breast cancer tissue microarray by immunohistochemistry. High SR-BI expression was observed in 54 % of all breast cancer cases and was significantly associated with advanced pTNM stage (P = 0.002), larger tumor size (P = 0.023), lymph node metastasis (P = 0.012), and the absence of ER (P = 0.014). The Kaplan–Meier survival analysis revealed that patients with high SR-BI expression had significantly shorter overall survival (OS) (P = 0.004). Moreover, multivariate analysis with adjustment for other prognostic factors confirmed that SR-BI was an independent prognostic factor for patient outcome (P = 0.017). Overall, our study demonstrated that high SR-BI expression was related to conventional parameters indicative of more aggressive tumor type and may serve as a new prognostic marker for poor clinical outcome in human breast cancer.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
ESM 1 (DOCX 228 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.